Updated on 19 July 2013
SMC Biotechnology licensed this novel platform technology from A*Star, Singapore's leader in fostering scientific development and talent. Through an exclusive agreement with A*Star, SMC Biotechnology was spun off from the Institute of Medical Biology in 2010 to commercialize a library of breakthrough GAG compounds that preferentially bind to separate pro-healing factors. SMC Biotechnology is currently developing SMC-103 for long bone healing and spinal fusion as an alternative to bone graft and bone graft substitutes.
"The collaboration between A*Star and SMC Biotechnology has been uniquely productive for both parties," says Mr Michael Crockett, co-founder and CEO of SMC Biotechnology. "Our collaboration with A*Star has allowed us to streamline the development of a pipeline of carbohydrates products, including a number of potential therapies that would be first-in-class in the world. SMC Biotechnology's important relationship with A*Star will generate many successful therapeutic strategies to fulfill multiple unmet medical needs in tissue regeneration worldwide. We look forward to taking the next step of studying SMC-103 in human bone repair with clinical trials in 2014," he added.